Mary Yang
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Computational Biology | 20 | 2018 | 231 | 2.740 |
Why?
| Systems Biology | 5 | 2018 | 33 | 2.190 |
Why?
| Algorithms | 22 | 2022 | 697 | 2.100 |
Why?
| Gene Expression Profiling | 14 | 2024 | 1141 | 1.710 |
Why?
| Single-Cell Analysis | 2 | 2024 | 56 | 1.600 |
Why?
| Promoter Regions, Genetic | 8 | 2010 | 520 | 1.580 |
Why?
| Artificial Intelligence | 13 | 2022 | 85 | 1.220 |
Why?
| Transcriptome | 5 | 2022 | 346 | 1.220 |
Why?
| Gene Regulatory Networks | 8 | 2021 | 124 | 1.210 |
Why?
| Sequence Analysis, RNA | 3 | 2024 | 107 | 1.070 |
Why?
| Genomics | 6 | 2018 | 313 | 1.060 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2022 | 48 | 1.040 |
Why?
| Proteins | 6 | 2010 | 376 | 0.960 |
Why?
| Quantitative Structure-Activity Relationship | 3 | 2008 | 29 | 0.950 |
Why?
| Pattern Recognition, Automated | 5 | 2009 | 45 | 0.820 |
Why?
| Mutation | 4 | 2018 | 1504 | 0.800 |
Why?
| Sequence Analysis, Protein | 3 | 2009 | 21 | 0.740 |
Why?
| Oligonucleotide Array Sequence Analysis | 8 | 2009 | 474 | 0.690 |
Why?
| Conserved Sequence | 2 | 2017 | 57 | 0.650 |
Why?
| Ovarian Neoplasms | 2 | 2016 | 474 | 0.640 |
Why?
| Sequence Analysis, DNA | 5 | 2009 | 274 | 0.630 |
Why?
| Models, Chemical | 2 | 2008 | 65 | 0.630 |
Why?
| Neurons | 1 | 2021 | 486 | 0.630 |
Why?
| Lung Neoplasms | 3 | 2018 | 643 | 0.600 |
Why?
| Genome, Human | 5 | 2018 | 131 | 0.600 |
Why?
| Drug Design | 2 | 2008 | 133 | 0.590 |
Why?
| Protein Interaction Mapping | 1 | 2016 | 44 | 0.570 |
Why?
| Genetic Research | 1 | 2014 | 4 | 0.520 |
Why?
| Brain | 3 | 2018 | 1392 | 0.500 |
Why?
| Breast Neoplasms | 2 | 2018 | 1249 | 0.490 |
Why?
| Ankyrins | 2 | 2010 | 10 | 0.490 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 868 | 0.460 |
Why?
| MicroRNAs | 5 | 2018 | 386 | 0.430 |
Why?
| Models, Molecular | 3 | 2008 | 423 | 0.430 |
Why?
| Genetic Predisposition to Disease | 4 | 2018 | 570 | 0.420 |
Why?
| Transcription Factor TFIID | 2 | 2010 | 4 | 0.420 |
Why?
| Biological Evolution | 2 | 2009 | 37 | 0.410 |
Why?
| Humans | 34 | 2022 | 54391 | 0.400 |
Why?
| Chromosome Mapping | 2 | 2009 | 175 | 0.400 |
Why?
| Sequence Alignment | 2 | 2008 | 146 | 0.390 |
Why?
| Spherocytosis, Hereditary | 1 | 2010 | 14 | 0.390 |
Why?
| Genome | 2 | 2009 | 74 | 0.390 |
Why?
| Genetic Techniques | 1 | 2010 | 15 | 0.380 |
Why?
| Transcription Factors | 2 | 2021 | 622 | 0.380 |
Why?
| Software | 3 | 2009 | 297 | 0.360 |
Why?
| Sequence Analysis | 1 | 2009 | 14 | 0.360 |
Why?
| Evolution, Molecular | 3 | 2010 | 103 | 0.350 |
Why?
| Congresses as Topic | 1 | 2009 | 52 | 0.340 |
Why?
| Gene Expression Regulation | 3 | 2021 | 1063 | 0.340 |
Why?
| Neoplasms | 6 | 2022 | 1322 | 0.330 |
Why?
| Databases, Genetic | 6 | 2018 | 101 | 0.330 |
Why?
| Vertebrates | 1 | 2008 | 11 | 0.330 |
Why?
| Open Reading Frames | 2 | 2018 | 55 | 0.330 |
Why?
| Neoplasm Proteins | 3 | 2008 | 360 | 0.330 |
Why?
| Artifacts | 1 | 2009 | 61 | 0.320 |
Why?
| Molecular Sequence Annotation | 2 | 2018 | 31 | 0.320 |
Why?
| Mammals | 1 | 2008 | 59 | 0.310 |
Why?
| RNA | 2 | 2024 | 202 | 0.310 |
Why?
| Pharmaceutical Preparations | 1 | 2008 | 86 | 0.300 |
Why?
| Protein Conformation | 5 | 2010 | 226 | 0.280 |
Why?
| Catechin | 2 | 2016 | 30 | 0.270 |
Why?
| Disease Progression | 2 | 2018 | 915 | 0.270 |
Why?
| Base Sequence | 5 | 2010 | 719 | 0.270 |
Why?
| Molecular Sequence Data | 6 | 2010 | 980 | 0.260 |
Why?
| Cluster Analysis | 2 | 2024 | 249 | 0.250 |
Why?
| Computer Simulation | 4 | 2008 | 332 | 0.240 |
Why?
| Probability | 1 | 2024 | 177 | 0.230 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2022 | 23 | 0.220 |
Why?
| CpG Islands | 2 | 2016 | 104 | 0.220 |
Why?
| Organogenesis | 1 | 2021 | 2 | 0.210 |
Why?
| Neural Stem Cells | 1 | 2021 | 27 | 0.200 |
Why?
| ROC Curve | 3 | 2018 | 259 | 0.200 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2021 | 44 | 0.200 |
Why?
| Databases, Protein | 3 | 2010 | 29 | 0.200 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 216 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2016 | 552 | 0.190 |
Why?
| Drug Resistance, Neoplasm | 1 | 2022 | 309 | 0.190 |
Why?
| Neoplasm Invasiveness | 2 | 2018 | 294 | 0.190 |
Why?
| Animals | 10 | 2017 | 14409 | 0.190 |
Why?
| Transcription Initiation Site | 2 | 2010 | 13 | 0.180 |
Why?
| Amino Acid Sequence | 4 | 2010 | 767 | 0.180 |
Why?
| Receptor, Melatonin, MT2 | 1 | 2018 | 1 | 0.170 |
Why?
| Neoplasm Staging | 2 | 2018 | 805 | 0.170 |
Why?
| Area Under Curve | 1 | 2018 | 205 | 0.160 |
Why?
| Amyloid beta-Peptides | 1 | 2018 | 82 | 0.160 |
Why?
| Diabetes Complications | 1 | 2018 | 123 | 0.160 |
Why?
| Forkhead Transcription Factors | 1 | 2018 | 118 | 0.160 |
Why?
| Neoplastic Stem Cells | 1 | 2018 | 104 | 0.160 |
Why?
| Protein Isoforms | 1 | 2017 | 124 | 0.150 |
Why?
| Peptide Fragments | 1 | 2018 | 242 | 0.150 |
Why?
| Protein Structure, Tertiary | 2 | 2008 | 289 | 0.150 |
Why?
| Proportional Hazards Models | 1 | 2018 | 430 | 0.150 |
Why?
| RNA, Messenger | 2 | 2014 | 1203 | 0.150 |
Why?
| Autistic Disorder | 1 | 2018 | 135 | 0.150 |
Why?
| Genetic Association Studies | 1 | 2018 | 136 | 0.150 |
Why?
| Urinary Bladder Neoplasms | 1 | 2018 | 173 | 0.150 |
Why?
| Proto-Oncogene Proteins c-myb | 1 | 2016 | 9 | 0.140 |
Why?
| Survival Analysis | 1 | 2018 | 736 | 0.140 |
Why?
| Neoplasm Grading | 1 | 2016 | 131 | 0.140 |
Why?
| Gastric Mucosa | 1 | 2016 | 59 | 0.140 |
Why?
| Models, Biological | 3 | 2008 | 825 | 0.130 |
Why?
| Models, Statistical | 4 | 2009 | 259 | 0.130 |
Why?
| Coronary Disease | 1 | 2016 | 166 | 0.130 |
Why?
| Transcription, Genetic | 3 | 2018 | 418 | 0.130 |
Why?
| Camellia sinensis | 1 | 2014 | 7 | 0.130 |
Why?
| Female | 9 | 2018 | 28471 | 0.130 |
Why?
| Binding Sites | 3 | 2010 | 440 | 0.130 |
Why?
| Anticarcinogenic Agents | 1 | 2014 | 35 | 0.130 |
Why?
| Triazines | 1 | 2014 | 30 | 0.130 |
Why?
| Inflammation | 2 | 2016 | 678 | 0.130 |
Why?
| Up-Regulation | 1 | 2016 | 509 | 0.120 |
Why?
| Polyphenols | 1 | 2014 | 55 | 0.120 |
Why?
| Consensus Sequence | 2 | 2010 | 25 | 0.120 |
Why?
| Alzheimer Disease | 1 | 2018 | 369 | 0.120 |
Why?
| Environmental Pollutants | 1 | 2014 | 101 | 0.120 |
Why?
| Stomach Neoplasms | 1 | 2016 | 174 | 0.110 |
Why?
| 5' Untranslated Regions | 2 | 2010 | 33 | 0.110 |
Why?
| Antineoplastic Agents | 1 | 2022 | 1300 | 0.110 |
Why?
| Least-Squares Analysis | 2 | 2009 | 45 | 0.110 |
Why?
| Base Composition | 2 | 2009 | 25 | 0.110 |
Why?
| Sequence Homology, Nucleic Acid | 2 | 2010 | 59 | 0.110 |
Why?
| Adenocarcinoma | 1 | 2016 | 428 | 0.100 |
Why?
| Signal Transduction | 4 | 2016 | 1752 | 0.100 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 462 | 0.100 |
Why?
| Genetic Diseases, Inborn | 2 | 2008 | 26 | 0.100 |
Why?
| K562 Cells | 1 | 2010 | 47 | 0.100 |
Why?
| Rats | 1 | 2017 | 3419 | 0.100 |
Why?
| Time Factors | 1 | 2017 | 3210 | 0.100 |
Why?
| Models, Genetic | 2 | 2008 | 209 | 0.090 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2010 | 41 | 0.090 |
Why?
| Aged, 80 and over | 2 | 2016 | 3431 | 0.090 |
Why?
| Obesity | 1 | 2018 | 1203 | 0.090 |
Why?
| DNA | 2 | 2010 | 581 | 0.090 |
Why?
| Protein Binding | 2 | 2010 | 736 | 0.090 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 79 | 0.090 |
Why?
| TATA Box | 1 | 2008 | 9 | 0.080 |
Why?
| Sample Size | 1 | 2009 | 48 | 0.080 |
Why?
| RNA Polymerase II | 1 | 2008 | 17 | 0.080 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2008 | 42 | 0.080 |
Why?
| Principal Component Analysis | 1 | 2008 | 71 | 0.080 |
Why?
| Radiotherapy, Adjuvant | 1 | 2008 | 66 | 0.080 |
Why?
| Sensitivity and Specificity | 2 | 2008 | 922 | 0.080 |
Why?
| Middle Aged | 4 | 2018 | 13082 | 0.080 |
Why?
| Tumor Burden | 1 | 2008 | 141 | 0.080 |
Why?
| Adrenal Cortex Neoplasms | 1 | 2008 | 7 | 0.080 |
Why?
| Cushing Syndrome | 1 | 2008 | 13 | 0.080 |
Why?
| DNA Repair | 1 | 2009 | 203 | 0.080 |
Why?
| Subcellular Fractions | 1 | 2008 | 43 | 0.080 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2008 | 55 | 0.080 |
Why?
| Mutagenicity Tests | 1 | 2008 | 56 | 0.080 |
Why?
| False Positive Reactions | 1 | 2008 | 68 | 0.080 |
Why?
| 14-3-3 Proteins | 1 | 2008 | 24 | 0.080 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 177 | 0.080 |
Why?
| Markov Chains | 1 | 2008 | 34 | 0.080 |
Why?
| Radiation Tolerance | 1 | 2008 | 87 | 0.080 |
Why?
| Protein Structure, Secondary | 1 | 2008 | 99 | 0.080 |
Why?
| Internet | 1 | 2010 | 275 | 0.080 |
Why?
| Health Services Research | 1 | 2008 | 165 | 0.080 |
Why?
| Expressed Sequence Tags | 1 | 2007 | 12 | 0.080 |
Why?
| Multigene Family | 1 | 2007 | 54 | 0.070 |
Why?
| Research | 1 | 2008 | 117 | 0.070 |
Why?
| Aged | 3 | 2016 | 10060 | 0.070 |
Why?
| Information Storage and Retrieval | 1 | 2007 | 64 | 0.070 |
Why?
| Biomedical Research | 1 | 2009 | 241 | 0.070 |
Why?
| Telomerase | 1 | 2006 | 30 | 0.070 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2008 | 251 | 0.070 |
Why?
| Pheochromocytoma | 1 | 2006 | 38 | 0.070 |
Why?
| Adrenal Gland Neoplasms | 1 | 2006 | 54 | 0.070 |
Why?
| Membrane Proteins | 1 | 2008 | 389 | 0.060 |
Why?
| Gene Expression | 1 | 2008 | 664 | 0.060 |
Why?
| Databases, Factual | 1 | 2008 | 683 | 0.060 |
Why?
| Odds Ratio | 2 | 2016 | 600 | 0.060 |
Why?
| Mice | 3 | 2014 | 6428 | 0.060 |
Why?
| Cell Line, Tumor | 2 | 2018 | 1551 | 0.060 |
Why?
| Risk Assessment | 1 | 2008 | 1362 | 0.050 |
Why?
| China | 2 | 2016 | 104 | 0.050 |
Why?
| Prognosis | 2 | 2018 | 2126 | 0.050 |
Why?
| Adult | 2 | 2016 | 14207 | 0.050 |
Why?
| Drug Discovery | 1 | 2022 | 90 | 0.050 |
Why?
| PubMed | 1 | 2018 | 10 | 0.040 |
Why?
| Species Specificity | 2 | 2009 | 206 | 0.040 |
Why?
| Axons | 1 | 2018 | 43 | 0.040 |
Why?
| Cattle | 2 | 2009 | 225 | 0.040 |
Why?
| Synapses | 1 | 2018 | 90 | 0.040 |
Why?
| Microarray Analysis | 2 | 2008 | 85 | 0.040 |
Why?
| In Situ Hybridization | 2 | 2008 | 82 | 0.040 |
Why?
| Receptors, Interleukin-1 Type II | 1 | 2016 | 2 | 0.040 |
Why?
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2016 | 10 | 0.040 |
Why?
| Treatment Outcome | 1 | 2008 | 5612 | 0.040 |
Why?
| Linkage Disequilibrium | 1 | 2016 | 47 | 0.040 |
Why?
| Cell Survival | 1 | 2018 | 657 | 0.040 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2016 | 40 | 0.040 |
Why?
| Gene Frequency | 1 | 2016 | 120 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2016 | 199 | 0.030 |
Why?
| Interleukin-1beta | 1 | 2016 | 92 | 0.030 |
Why?
| Stomach | 1 | 2016 | 81 | 0.030 |
Why?
| Lymphatic Metastasis | 1 | 2016 | 256 | 0.030 |
Why?
| Nitrosamines | 1 | 2014 | 8 | 0.030 |
Why?
| Genotype | 1 | 2016 | 600 | 0.030 |
Why?
| Cell Proliferation | 1 | 2018 | 1097 | 0.030 |
Why?
| Neurotoxicity Syndromes | 1 | 2014 | 52 | 0.030 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2014 | 170 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 176 | 0.030 |
Why?
| Antioxidants | 1 | 2016 | 297 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2014 | 198 | 0.030 |
Why?
| Carcinogens | 1 | 2014 | 231 | 0.030 |
Why?
| Male | 4 | 2018 | 27347 | 0.030 |
Why?
| NF-kappa B | 1 | 2014 | 336 | 0.030 |
Why?
| Lung | 1 | 2016 | 508 | 0.030 |
Why?
| Apoptosis | 1 | 2018 | 1302 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2014 | 1664 | 0.020 |
Why?
| Cell-Free System | 1 | 2010 | 16 | 0.020 |
Why?
| TATA-Box Binding Protein | 1 | 2010 | 7 | 0.020 |
Why?
| Gene Library | 1 | 2010 | 50 | 0.020 |
Why?
| Sequence Deletion | 1 | 2010 | 99 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 225 | 0.020 |
Why?
| Synteny | 1 | 2009 | 7 | 0.020 |
Why?
| Animals, Domestic | 1 | 2009 | 8 | 0.020 |
Why?
| RecQ Helicases | 1 | 2009 | 19 | 0.020 |
Why?
| Alternative Splicing | 1 | 2009 | 64 | 0.020 |
Why?
| Mathematical Computing | 1 | 2008 | 7 | 0.020 |
Why?
| Poisson Distribution | 1 | 2008 | 32 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2010 | 658 | 0.020 |
Why?
| Phylogeny | 1 | 2009 | 269 | 0.020 |
Why?
| Biomedical Technology | 1 | 2008 | 9 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2008 | 82 | 0.020 |
Why?
| Drug Therapy | 1 | 2008 | 50 | 0.020 |
Why?
| Genetic Variation | 1 | 2009 | 253 | 0.020 |
Why?
| Risk Factors | 1 | 2016 | 3937 | 0.020 |
Why?
| Forecasting | 1 | 2008 | 161 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2008 | 193 | 0.020 |
Why?
| Proteomics | 1 | 2009 | 343 | 0.020 |
Why?
| Adrenal Medulla | 1 | 2006 | 5 | 0.020 |
Why?
| Bacteria | 1 | 2008 | 258 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 674 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 21 | 0.020 |
Why?
| Research Design | 1 | 2008 | 375 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2006 | 63 | 0.020 |
Why?
| Logistic Models | 1 | 2008 | 991 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2008 | 1090 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2008 | 1301 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2006 | 2390 | 0.010 |
Why?
| Adolescent | 1 | 2006 | 6900 | 0.010 |
Why?
|
|
Yang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
|